How KPV Works — Two Mechanisms, Two Concentration Ranges

Summary

KPV is Lys-Pro-Val, the last three residues of alpha-melanocyte-stimulating hormone. At thirteen residues, the parent hormone acts through melanocortin receptors. At three, KPV does not — and that is the single most misreported fact about it.

The published literature describes two separate mechanisms operating at two separate concentration ranges:

• At nanomolar concentrations, KPV is carried into cells intact by the peptide transporter PepT1 and suppresses NF-κB signalling from the inside.
• At micromolar concentrations, KPV kills bacteria by disrupting their membranes — a physical effect with no transporter involved.

A thousand-fold difference in concentration, two entirely different modes of action. If a protocol is written without deciding which one it is testing, the result is difficult to interpret whichever way it goes.

What KPV Is

KPV is a tripeptide: Lys-Pro-Val, molecular formula C₁₆H₃₀N₄O₄, molecular weight 342.44 g/mol, PubChem CID 125672, CAS 67727-97-3.

It corresponds to residues 11–13 of alpha-MSH — the C-terminal end of a hormone whose full sequence runs to thirteen residues. In the literature it is often written as α-MSH(11–13), and searching that term returns papers that searching “KPV” alone will miss.

Three residues makes it one of the smallest compounds in the research-peptide catalogue. That size drives almost everything else about how it behaves: high aqueous solubility, a different degradation profile from longer chains, and, critically, eligibility for transport by systems that handle di- and tripeptides rather than proteins. The full chemical identity and evidence grading sit on the KPV compound profile; this article is about mechanism.

Mechanism One — PepT1 Uptake and NF-κB

The central paper here is Dalmasso and colleagues, published in Gastroenterology in 2008.¹ It is worth describing in some detail, because it is the source most often cited and least often read.

The work used cultured human intestinal epithelial cells (Caco2-BBE and HT29-Cl.19A), human Jurkat T cells, and two mouse models of colitis induced with DSS and with TNBS. Inflammatory signalling was measured by NF-κB luciferase reporter, Western blot, real-time RT-PCR and ELISA. Uptake was tracked using tritiated KPV.

The finding: KPV is taken up intact by PepT1, a transporter expressed on both intestinal epithelial and immune cells, and suppresses inflammatory signalling at nanomolar concentrations. In the animal models, orally administered KPV reduced the severity of colitis and the expression of inflammatory cytokines.

Two details matter and are routinely lost in summary.

It is a transporter, not a receptor

PepT1 exists to move di- and tripeptides across membranes as nutrients. KPV is small enough to qualify as cargo. It is not binding a signalling receptor on the cell surface and triggering a cascade — it is being carried inside and acting there. This is why the effect appears at nanomolar concentrations: transporters concentrate their substrate rather than requiring saturating amounts of it.

It explains the oral route in the studies

PepT1 is heavily expressed in the small intestine, and in inflamed colonic tissue. A tripeptide that this transporter recognises can be delivered to the gut and taken up there without needing to survive the journey a larger peptide would face. That is a property of the molecule, not a recommendation about how anyone should use it.

Mechanism Two — Membrane Disruption

Separately, and at concentrations roughly a thousand times higher, KPV is antibacterial.

Singh and Mukhopadhyay, publishing in Antimicrobial Agents and Chemotherapy in 2011, tested alpha-MSH fragments against methicillin-sensitive and methicillin-resistant Staphylococcus aureus.² The C-terminal fragment α-MSH(11–13) — KPV — killed more than 90% of both strains in the micromolar range, matching the activity of the full-length hormone. The N-terminal regions did not. The proposed mechanism is membrane disruption.

Earlier work had already reported antimicrobial effects for alpha-MSH peptides against Candida albicans and S. aureus.³ The 2011 paper is useful because it localises the activity to the exact three residues that KPV consists of.

Why the Concentration Range Decides the Experiment

Put the two findings side by side and the gap is stark.

Working out the molar concentration of a KPV solution is straightforward given the molecular weight. A 10mg vial taken to 2ml gives 5 mg/ml; dividing by 342.44 g/mol puts that at roughly 14.6 millimolar as a stock. Reaching nanomolar working concentrations from there means serial dilution over several orders of magnitude — and at those dilutions, adsorption to plasticware stops being a rounding error and starts being the dominant loss. Our reconstitution guide covers that problem directly, and the calculator handles the mg/ml step.

KPV vs BPC-157

These two get compared constantly, almost always without reference to what either literature contains.

They are not variants of one another and they do not share a research lineage. KPV is a three-residue fragment of a melanocortin hormone with a documented transporter-mediated mechanism. BPC-157 is a fifteen-residue sequence derived from a protein found in gastric juice, with a separate preclinical literature of its own. No study has run them head to head, so any ranking between them is assertion rather than evidence.

The honest position is that they answer different questions. Our BPC-157 research guide covers that literature on its own terms.

KPV vs Full-Length Alpha-MSH

This comparison is more useful, because the two are genuinely related and the difference is instructive.

Alpha-MSH is thirteen residues and acts at melanocortin receptors — the same receptor family that Melanotan I and PT-141 are studied against. Cut it down to the last three residues and that receptor activity is not what remains. KPV retains anti-inflammatory and antibacterial activity while shedding the pigmentary and receptor-agonist properties of the parent.

A 2003 paper in The Journal of Pharmacology and Experimental Therapeutics dissected the anti-inflammatory contribution of the core and C-terminal portions of alpha-MSH specifically to establish which part was doing what.⁴ That kind of fragment-by-fragment work is why KPV exists as a separate research article at all rather than as a footnote to the hormone.

What the Evidence Does Not Show

Three limits are worth stating plainly, because they are widely ignored.

The colitis work is animal and cell-culture research

DSS and TNBS colitis models are chemically induced inflammation in mice. They are standard tools and they are not human disease. Nothing in the Dalmasso paper establishes an effect in people, and it does not claim to.

Topical activity is not established by the anti-inflammatory data

KPV is small and water-soluble, which is not the same as skin-permeable. Published work on delivering KPV across human skin has used iontophoresis through microporated tissue — that is, active electrical driving through a physically breached barrier.⁵ That research exists precisely because passive permeation through intact skin is not straightforward.

Purity is not potency

A 98% or 99% HPLC figure describes the chromatographic purity of a tested sample under a stated method. It says nothing about biological activity, and for a tripeptide it says nothing about how much of the vial mass is peptide rather than counterion and residual water. Our guide to what purity figures actually mean works through that distinction.

Handling KPV in the Laboratory

Three residues, none of them fragile: Lys-Pro-Val contains no methionine, no cysteine and no tryptophan, so the oxidation problems that constrain solvent choice for sequences like Semax do not apply here.

It is also highly water-soluble. Bacteriostatic water is the standard diluent and no co-solvent should be required — if a vial resists going into solution, the vial is the more likely explanation than the method. Store the sealed lyophilised powder at 2–8°C away from light, and once in solution refrigerate and aliquot into single-use portions so the stock takes one freeze-thaw cycle rather than one per use.

Pureline’s current batch is PLB-011, reported at 98.015% by HPLC at Janoshik Analytical, with the certificate published on the lab reports page before the stock was listed. You can buy KPV 10mg here.

What KPV Is Used For in Research

Setting aside what it is marketed for, here is where KPV actually appears in the published literature.

• Intestinal inflammation models. The largest body of work. Chemically induced colitis in mice, plus human intestinal epithelial cell lines, measuring NF-κB activation and inflammatory cytokine expression.
• Peptide transporter studies. KPV is a substrate for PepT1, so it appears in work characterising how that transporter handles di- and tripeptides, and in nanoparticle delivery research built around it.
• Antibacterial screening. Against Staphylococcus aureus including methicillin-resistant strains, and in earlier work on alpha-MSH peptides against Candida albicans.
• Structure-activity work on alpha-MSH. Fragment-by-fragment dissection of which part of the parent hormone carries which activity — the research that established KPV as a compound worth studying separately.

All of it is in vitro or animal work. There are no published human clinical trials of KPV, and the compound has no approved use anywhere.

What People Mean by KPV Benefits

This phrase gets searched a great deal, and it deserves a straight answer rather than a dodge.

“Benefit” implies an established effect in a person. Nothing in the KPV literature supports that word. What the research reports is narrower and more specific: reduced NF-κB signalling in cultured cells, reduced histological damage and cytokine expression in mice given a chemical colitis inducer, and bacterial killing in a dish. Those are measurements, made in systems chosen because they are tractable, not because they are people.

The distance between the two is not a technicality. A DSS colitis model is inflammation deliberately induced in a mouse over a few days by putting a detergent in its drinking water. It is a standard and useful research tool. It is not inflammatory bowel disease, and a compound that changes a readout in that model has not been shown to do anything for a person.

Pureline supplies KPV as a laboratory research material, and that is the only claim we make about it. We do not publish benefit claims, use cases for people, or dosing information, because none of those things follow from the evidence.

Common Questions

What are KPV peptides?

KPV is a single peptide rather than a family — a tripeptide of lysine, proline and valine, corresponding to the last three residues of alpha-melanocyte-stimulating hormone. The plural usually turns up because people are thinking of the broader group of alpha-MSH fragments studied for anti-inflammatory activity, of which KPV is the shortest and most studied.

What is KPV peptide used for?

In published research: models of intestinal inflammation, studies of the PepT1 peptide transporter, antibacterial screening against Staphylococcus aureus, and structure-activity work on alpha-MSH fragments. It has no approved use in humans or animals anywhere, and Pureline supplies it strictly as a laboratory research material.

What are the benefits of KPV?

None have been established in people, because no human trials have been published. The research reports specific measurements in specific systems — NF-κB suppression in cultured cells, reduced damage in chemically induced mouse colitis, bacterial killing in vitro. Those are findings in laboratory models, not benefits, and treating them as the same thing is the most common error made about this compound.

How much KPV should I take?

We cannot answer that, and no legitimate UK supplier can. KPV has no UK marketing authorisation, no approved human use, and no established human dosing — there is no clinical research from which a figure could be derived. The concentrations in the published literature are cell culture and animal model figures, and they do not translate. Pureline supplies KPV for in vitro laboratory research only and does not provide dosing guidance of any kind.

Does KPV have side effects?

Unknown, in the strict sense: there is no published human safety data on KPV, no characterised interaction profile, and no studies that examined mood, cognitive or neurological endpoints at all. An absence of reported effects is not evidence of safety — it reflects that the studies have not been done. Anyone weighing this up should treat the compound as uncharacterised in humans, because that is what it is.

How does KPV work?

Through two documented mechanisms at different concentrations. At nanomolar levels it is transported into cells intact by PepT1 and suppresses NF-κB inflammatory signalling. At micromolar levels it disrupts bacterial membranes directly. It does not act at melanocortin receptors the way its parent hormone does.

Is KPV the same as alpha-MSH?

No. KPV is the final three residues of alpha-MSH, written α-MSH(11–13). The full hormone is thirteen residues and acts at melanocortin receptors; the tripeptide fragment does not, but retains anti-inflammatory and antibacterial activity.

KPV or BPC-157 — which is better?

Neither, because no study has compared them. They come from unrelated sources, have different documented mechanisms and are studied against different endpoints. Any ranking you find is opinion presented as fact.

Why do the studies give KPV orally?

Because PepT1, the transporter that takes it up, is heavily expressed in intestinal tissue, so oral delivery in an animal colitis model puts the compound where the transporter is. That is a description of the published methodology, not guidance for any other use.

What concentration is used in KPV research?

It depends entirely on which mechanism is being studied: nanomolar for the anti-inflammatory work, micromolar for the antibacterial work. The two differ by roughly a thousand-fold, which is why a protocol needs to specify which literature it is following.

Does KPV work on the skin?

The published human-skin delivery work used iontophoresis across microporated skin rather than passive application, which indicates that getting KPV through an intact barrier is not straightforward. The anti-inflammatory data does not by itself establish topical activity.

Is KPV antimicrobial?

In published in vitro work, yes — the alpha-MSH C-terminal fragment killed over 90% of methicillin-sensitive and methicillin-resistant Staphylococcus aureus in the micromolar range, apparently by membrane disruption. This is laboratory antibacterial activity, not a clinical finding.

How much bacteriostatic water does a 10mg KPV vial need?

2ml gives 5 mg/ml and 3ml gives roughly 3.33 mg/ml. Against a molecular weight of 342.44 g/mol, 5 mg/ml is about 14.6mM as a stock solution.

Is KPV legal to buy in the UK?

It is supplied strictly as a research chemical for in vitro laboratory use. KPV holds no UK marketing authorisation, is not a licensed medicine here, and is not sold for human or veterinary use. The UK peptide law guide sets out how research-use materials sit within the regulations.

References

1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. DOI: 10.1053/j.gastro.2007.10.026 · PubMed 18061177
2. Singh M, Mukhopadhyay K. C-terminal amino acids of alpha-melanocyte-stimulating hormone are requisite for its antibacterial activity against Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(5):1920–1929. DOI: 10.1128/AAC.00957-10 · PubMed 21282427
3. Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. PubMed 10670585
4. Getting SJ, Christian HC, Lam CW, et al. Dissection of the anti-inflammatory effect of the core and C-terminal KPV alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631–637. PubMed 12750433
5. Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. J Pharm Sci. ScienceDirect

Published by Pureline Biolabs Ltd, a UK-registered supplier of laboratory research materials, company number 17236739. Last reviewed September 2026. Pureline did not conduct the studies listed above; our contribution is the organisation of the evidence, the limits placed around its interpretation, and the publication of analytical records for our own stock. Factual corrections are welcome through the contact page.